SEC Tracker
Get the app

Adial Pharmaceuticals AZR

Adial Pharmaceuticals reports $52M net loss

Form
10-Q/A
Filed
Importance
Routine
  1. Net loss: $51.99 million for the three months ended Jun 30, 2026
  2. Diluted EPS: -$11.25 for the three months ended Jun 30, 2026
  3. Cash and equivalents: $28.71 million at Jun 30, 2026

Written from the 10-Q/A on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Adial Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. AIM ImmunoTech AIM public float $6M, Jun 30, 2025
  2. Vyome Holdings HIND public float $6M, Jun 30, 2025
  3. Biomerica BMRA public float $7M, Nov 28, 2025
  4. Protagenic Therapeutics, Inc.\new PTIX public float $7M, Sep 30, 2025
  5. PharmaCyte Biotech PMCB public float $6M, Oct 31, 2025